NCT06616571 2024-09-27
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Qilu Pharmaceutical Co., Ltd.
Phase 4 Recruiting
Clinical Trials
13 trialsNCT03104595 2023-08-15
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
Enzychem Lifesciences Corporation
Phase 1/2 Completed
NCT04477616 2023-02-23
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT02728596 2022-10-20
TrACER
SWOG Cancer Research Network
Phase NA Completed
NCT02685111 2020-07-31
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Asan Medical Center
Phase 2 Terminated
NCT00536081 2019-11-06
Various G-CSF Regimens to Prevent Infection During Chemotherapy
Academisch Ziekenhuis Maastricht
Phase 3 Completed
NCT03618810 2018-12-27
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
Zhejiang Cancer Hospital
Unknown
NCT02005458 2018-07-17
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 2 Completed
NCT01569087 2016-12-05
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Biocad
Phase 2 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01459653 2016-01-11
Monitor-GCSF
Sandoz
Completed
NCT02119715 2014-04-22
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01611051 2013-01-08
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed